Small molecule · Antagonist of neurokinin 1 receptor (TACR1) · developed by Vanda Pharms
Tradipitant is a selective antagonist of neurokinin 1 (NK1) receptors that crosses the blood-brain barrier. It blocks substance P signaling in the central nervous system to prevent motion-induced vomiting and is being studied for gastroparesis and pruritus associated with atopic dermatitis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 16, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06836557 | Phase 3 | Idiopathic Gastroparesis | Recruiting | VNDA |
| NCT04028492 | Phase 3 | Idiopathic Gastroparesis | Completed | VNDA |
| NCT02970968 | Phase 2 | Gastroparesis | Completed | VNDA |
| NCT02004041 | Phase 2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | Completed | VNDA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetic GastroparesisGastroparesisIdiopathic Gastroparesis
Updated Oct 3, 2026. Something wrong or missing? Report it on the VNDA page.
See VNDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VNDA catalysts and pipeline →